

### **EVALUATION OF THE USE OF INFLIXIMAB IN IMMUNE-CHECKPOINT INHIBITOR-INDUCED ADVERSE REACTIONS**



Cremades Artacho C<sup>1</sup>, Carcelero San Martin E<sup>1</sup>, Carro Méndez I<sup>1</sup>, Rial Domínguez Y<sup>1</sup>, Monge Escartín I<sup>1</sup>, Riu Viladoms G<sup>1</sup>, Arance Fernández A<sup>2</sup>, Soy Muner D<sup>1</sup>. <sup>1</sup>Pharmacy Service. Division of Medicines. Hospital Clínic Barcelona, Spain

<sup>2</sup>Medical Oncological Service. Hospital Clínic Barcelona, Spain

### **Background and Importance**

checkpoint inhibitors (ICIs) Immune have transformed cancer treatment. However, their use can lead to immune-related adverse events (irAES). Corticosteroids are the first-line treatment; in


# **Aim and Objectives**

To evaluate the efficacy of infliximab in treating irAEs in cancer patients receiving ICIs.



## **Materials and Methods**

• A retrospective observational study was conducted at a tertiary care teaching hospital, including demographic, clinical, and efficacy data of patients treated with infliximab for irAEs from January 2011 to October 2024.



58.1% of patients received Infliximab during hospitalization and 41.9% in oncology day hospital Only 29.1% resumed immunotherapy after infliximab treatment, with one patient experiencing recurrence of the irAE.

### **Conclusion and Relevance**

Infliximab was effective in treating immune-mediated colitis and diarrhea, reducing steroid dosages. However, it was no beneficial in cases of immune-mediated pneumonitis. Less severely ill patients can receive infliximab safely in oncology day hospital.



